- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT00297362
A Study of the Safety and Effectiveness of Galantamine Hydrobromide in Patients With Alzheimer's Disease
March 23, 2012 updated by: Janssen Cilag Pharmaceutica S.A.C.I., Greece
Open Observational Study of Galantamine Hydrobromide Administration for the Treatment of Patients With Mild to Moderate Dementia of the Alzheimer Type
The purpose of this study is to evaluate the safety and effectiveness of galantamine hydrobromide in patients with Alzheimer's disease who have not received or have not responded to treatment with medication similar to galantamine hydrobromide.
Study Overview
Status
Completed
Conditions
Intervention / Treatment
Detailed Description
Galantamine hydrobromide is a medication that is approved for the treatment of symptoms of Alzheimer's disease.
In accordance with international guidelines, studies are conducted after a drug is marketed to continue to evaluate and expand the knowledge regarding its safety.
This is a multi-center, open-label (all people involved know the identity of the intervention), observational study (individuals are observed or certain outcomes are measured - no attempt is made to affect the outcome) to collect information regarding the safety and effectiveness of galantamine hydrobromide in patients with Alzheimer's disease.
Patients who have been prescribed galantamine hydrobromide as initial treatment with this type of medication for their Alzheimer's disease or who have failed previous treatment with similar medication of this type for their Alzheimer's disease will receive galantamine hydrobromide for 6 months.
The individual physicians responsible for the treatment of Alzheimer's disease will administer galantamine hydrobromide at doses appropriate for each patient and will continue to oversee their care.
No medication will be supplied by the sponsor of this study.
Safety evaluations (incidence of adverse events, physical exams, vital signs and laboratory tests) will be performed throughout the study.
Effectiveness will be determined using standard tests and rating scales to assess mental status, functioning, thinking, behavior, judgment and language (Neuropsychiatric Inventory, [NPI], Mini Mental Status Exam [MMSE] and Clinical Global Impression-Caregiver [CGI-Caregiver]).
Assessments will be conducted monthly for the first 3 months and at the end of 6 months of treatment.
Galantamine hydrobromide treatment should be discontinued if there is no further indication of effectiveness.
At the end of the study, the treating physician may continue treatment with galantamine hydrobromide in responding patients as appropriate.
The study hypothesis is that galantamine hydrobromide will be effective in treating the symptoms associated with Alzheimer's disease and is safe and well-tolerated.
Observational study -No investigational drug administered
Study Type
Observational
Enrollment (Actual)
344
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
- ADULT
- OLDER_ADULT
- CHILD
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Sampling Method
Probability Sample
Study Population
247 patients with diagnosed with mild to moderate Alzheimer's disease with a score of 10-26 on the Mini Mental Status Exam.
Patients switching from an acetylcholinesterase inhibitor treatment due to lack of efficacy or poor tolerability.
Description
Inclusion Criteria:
- Patients with a score of 10-26 on the Mini Mental Status Exam
- Patients who have not yet received treatment for their Alzheimer's disease with a medication similar to galantamine or patients who have been treated with as medication similar to galantamine hydrobromide and who have discontinued that medication due to lack of effectiveness or poor tolerability (adverse events)
Exclusion Criteria:
- Patients with severely decreased liver or kidney function
- Patients with a digestive system or urinary blockage who are recovering from digestive system or urinary bladder surgery
- Patients with clinically significant unstable or uncontrolled hormonal or mental disease
- Patients who are unable to take the medication either alone or with help from another person who is available during the entire study period
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
Cohorts and Interventions
Group / Cohort |
Intervention / Treatment |
---|---|
Galantamine hydrobromide
|
247 patients with diagnosed mild to moderate Alzheimer disease.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Changes from baseline in Mini-Mental State Examination (MMSE) scale scores
Time Frame: Baseline to 6 months
|
The MMSE is a brief 30-point questionnaire test that is used to screen for cognitive impairment.
A score greater than or equal to 25 points is effectively normal (intact).
Below this, scores can indicate severe (≤9 points), moderate (10-20 points) or mild (21-24 points) cognitive impairment.
|
Baseline to 6 months
|
Changes from baseline in Disability Assessment for Dementia (DAD) scale scores
Time Frame: Baseline to 6 months
|
The 40-item DAD scale assesses functional abilities in activities of daily living in patients with dementia and other cognitive impairments.
Higher scores indicate less disability while lower scores denote more difficulties.
|
Baseline to 6 months
|
Changes from baseline in Neuropsychiatric Inventory (NPI) scale scores
Time Frame: Baseline to 6 months
|
The NPI assesses psychopathology in dementia patients.
It evaluates 12 neuropsychiatric disturbances common in dementia: delusions, hallucinations, agitation, dysphoria, anxiety, apathy, irritability, euphoria, disinhibition, aberrant motor behavior, night-time behavior disturbances, and appetite and eating abnormalities.
Both the frequency (from rarely to very often) and the severity (from mild to severe) of each behavior are determined.
|
Baseline to 6 months
|
Changes from baseline in Clinical Global Impression (CGI) scale scores
Time Frame: Baseline to 6 months
|
The CGI-S rating scale is a 7 point global assessment that measures the clinician's impression of the severity of illness exhibited by a patient.
A rating of 1 is equivalent to "Normal, not at all ill" and a rating of 7 is equivalent to "Among the most extremely ill patients".
|
Baseline to 6 months
|
Changes from baseline in Cornell Scale
Time Frame: Baseline to 6 months
|
The Cornell Scale assesses signs and symptoms of major depression in patients with dementia.
Each item is rated for severity on a scale of 0-2 (0=absent, 1=mild or intermittent, 2=severe).
The item scores are added.
Scores above 10 indicate a probable major depression.
Scores above 18 indicate a definite major depression.
Scores below 6 as a rule are associated with absence of significant depressive symptoms.
|
Baseline to 6 months
|
Secondary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Number of patients with Adverse Events as Measure of Safety and Tolerability
Time Frame: 6 months
|
6 months
|
Number of patients whose vital signs fell outside the normal ranges
Time Frame: 6 months
|
6 months
|
Number of patients whose laboratory test results fell outside the normal ranges
Time Frame: 6 months
|
6 months
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Publications and helpful links
The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start
June 1, 2004
Study Completion (ACTUAL)
October 1, 2005
Study Registration Dates
First Submitted
February 24, 2006
First Submitted That Met QC Criteria
February 24, 2006
First Posted (ESTIMATE)
February 28, 2006
Study Record Updates
Last Update Posted (ESTIMATE)
March 26, 2012
Last Update Submitted That Met QC Criteria
March 23, 2012
Last Verified
March 1, 2012
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
- Mental Disorders
- Brain Diseases
- Central Nervous System Diseases
- Nervous System Diseases
- Neurocognitive Disorders
- Neurodegenerative Diseases
- Dementia
- Tauopathies
- Alzheimer Disease
- Physiological Effects of Drugs
- Neurotransmitter Agents
- Molecular Mechanisms of Pharmacological Action
- Autonomic Agents
- Peripheral Nervous System Agents
- Cholinergic Agents
- Enzyme Inhibitors
- Nootropic Agents
- Cholinesterase Inhibitors
- Parasympathomimetics
- Galantamine
Other Study ID Numbers
- CR003559
- 57504DEM4001 (OTHER: Janssen Cilag Pharmaceutica S.A.C.I., Greece)
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Alzheimer Disease
-
ProgenaBiomeRecruitingAlzheimer Disease | Alzheimer Disease, Early Onset | Alzheimer Disease, Late Onset | Alzheimer Disease 1 | Alzheimer Disease 2 | Alzheimer Disease 3 | Alzheimer Disease 4 | Alzheimer Disease 7 | Alzheimer Disease 17 | Alzheimer Disease 5 | Alzheimer Disease 6 | Alzheimer Disease 8 | Alzheimer Disease 10 | Alzheimer... and other conditionsUnited States
-
Cognito Therapeutics, Inc.RecruitingCognitive Impairment | Dementia | Alzheimer Disease | Mild Cognitive Impairment | Cognitive Decline | Alzheimer Disease, Early Onset | Alzheimer Disease, Late Onset | MCI | Dementia Alzheimers | Mild Dementia | Dementia of Alzheimer Type | Cognitive Impairment, Mild | Alzheimer Disease 1 | Dementia, Mild | Alzheimer... and other conditionsUnited States
-
AphiosNot yet recruitingDementia | Alzheimer Disease 1 | Alzheimer Disease 2 | Alzheimer Disease 3
-
Capital Medical UniversityPeking University First Hospital; The First Affiliated Hospital of Anhui Medical... and other collaboratorsRecruitingAlzheimer Disease | Familial Alzheimer Disease (FAD)China
-
University of PennsylvaniaNational Institute on Aging (NIA)CompletedDementia | Alzheimer Disease, At Risk | Alzheimer Disease, Protection AgainstUnited States
-
Kyoto UniversityOsaka University; Mie University; Tokushima University; Tokyo Metropolitan Geriatric... and other collaboratorsCompletedFamilial Alzheimer Disease (FAD) | PSEN1 MutationJapan
-
University of ArizonaNational Institute on Aging (NIA); University of Southern California; Syneos... and other collaboratorsRecruitingNeurodegenerative Diseases | Alzheimer Dementia | Late Onset Alzheimer DiseaseUnited States
-
National Taiwan Normal UniversityCompletedAlzheimer Disease 2 Due to Apoe4 IsoformTaiwan
-
Northwell HealthRecruitingAlzheimer Disease | Alzheimer Disease With Delusions | Alzheimer Disease With PsychosisUnited States
-
University of Kansas Medical CenterNational Institute on Aging (NIA)CompletedHealthy Aging | Alzheimer Disease 2 Due to Apoe4 IsoformUnited States
Clinical Trials on Galantamine hydrobromide
-
Johnson & Johnson Pharmaceutical Research & Development...CompletedFrontotemporal Dementia | Pick Complex
-
Johnson & Johnson Pharmaceutical Research & Development...Completed
-
Johnson & Johnson Pharmaceutical Research & Development...CompletedDementia | Alzheimer Disease
-
Johnson & Johnson Pharmaceutical Research & Development...CompletedAlzheimer Disease | Vascular Dementia
-
Janssen Pharmaceutica N.V., BelgiumCompleted
-
Johnson & Johnson Pharmaceutical Research & Development...Completed
-
Johnson & Johnson Pharmaceutical Research & Development...CompletedDementia | Alzheimer Disease
-
Johnson & Johnson Pharmaceutical Research & Development...CompletedMental Disorders | Brain Diseases | Nervous System Diseases | Cognition Disorder
-
Janssen-Cilag S.p.A.CompletedMental Disorders | Brain Diseases | Dementia | Alzheimer Disease
-
Janssen Korea, Ltd., KoreaCompleted